Skip to main content
. 2022 Jun 19;65(8):815–823. doi: 10.1111/myc.13476

FIGURE 2.

FIGURE 2

Percentage of hospitalised patients with COVID‐19 who received immunomodulatory therapies stratified based on a diagnosis of cryptococcosis. The figure compares the percentage of hospitalised patients with COVID‐19 with cryptococcosis (cases) to those without cryptococcosis (controls) who received dexamethasone, tocilizumab, or baricitinib. The asterisks denotes a statistically significant difference between groups